DrugDashboards

Permethrin

Permethrin Cream 5% w/w · PERMETHRIN 50 mg/g · Cream · Topical · Encube Ethicals, Inc.

NDC 21922-0021-07 · 1 TUBE in 1 CARTON / 60 g in 1 TUBE · ANDA · View full market →

The short version

Just 3 companies supply this market — thin enough that a single exit would be felt immediately. The price has held steady around $0.2314 per gram over the past year. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$0.2314per GMinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$0.6643per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$0.4007per unitnegotiated price across 5,496 plans — before rebates · Apr 1, 2026
  • Medicaid generic ceiling (FUL)$0.2314per GMweighted avg manufacturer price $0.0826 · Aug 1, 2026100% of what pharmacies pay — higher than 10% of drugs with this benchmark

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$0.4007per unit
middle half $0.3070$0.4946 · 5,496 plans · Apr 1, 2026
Est. net of rebates
≈ $0.4007
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
100%of plans cover it
tier 3 · prior auth 0% · step therapy 0% · qty limit 26%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$0.2$0.4$0.6Oct 2019Sep 2026$0.2314
84 price points · per GM · dashed = manufacturer avg (WAMP)Source: CMS NADAC

Medicaid spend (2025)

$2.6M
109,731 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

10Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 3 active manufacturers+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for permethrin cream 5% w/w (other) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA211303
TE code
AB
Approval date
Apr 3, 2019
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Permethrin Cream 5% w/w (Cream)

LabelerStrengthFirst seenLast seen
Encube Ethicals, Inc.PERMETHRIN 50 mg/gJul 15, 2026Sep 2, 2026
Preferred Pharmaceuticals Inc.PERMETHRIN 50 mg/gJul 15, 2026Sep 2, 2026
Remedyrepack Inc.PERMETHRIN 50 mg/gJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Permethrin — NDC 21922-0021-07," retrieved September 3, 2026, https://drugdashboards.com/drug/21922002107.

Free to cite with attribution — see how the data is put together.